Laurence Zitvogel, MD, PhD
The European Society for Medical Oncology (ESMO) has granted the newly established ESMO Award for Immuno-Oncology to Laurence Zitvogel, MD, PhD, for her innovating and internationally recognized achievements in the field.
Dr. Zitvogel is Professor of Immunobiology at the University of Paris XI Medical School and Scientific Director at the Department of Immuno-Oncology, Gustave Roussy Cancer Centre, in Villejuif, France. She is also Director of U1015 INSERM Tumor Immunology and Immunotherapy Laboratory at INSERM and Co-Director of the Centre for Clinical Investigation in Biotherapies of Cancer, INSERM.
“Professor Zitvogel’s discoveries in the area of immuno-oncology have served as the foundation for important advances and our understanding of the fundamentals of cancer immunology,” said Christoph Zielinski, on behalf of the ESMO Fellowship and Award Committee. “In presenting her with the ESMO Award for Immuno-Oncology we are recognising her preeminent and pioneering role in the field,” noted Mr. Zielinski.
Professor Zitvogel’s discoveries in the area of immuno-oncology have served as the foundation for important advances and our understanding of the fundamentals of cancer immunology.— Christoph Zielinski, ESMO Fellowship and Award Committee
Tweet this page
Dr. Zitvogel has dedicated her career to advancing the field of cancer immunology and immunotherapy. She is a devoted educator having directed the work of many postdoctoral fellows. She has authored or coauthored over 350 publications and is also Editor-in-Chief and Founder of one of the first journals in immune-oncology, OncoImmunology.
Her current research falls into three main categories: studying the modes of action of immune checkpoint inhibitors and seeking predictors of response to immunomodulators; defining the role of the gut microbiome in cancer immunosurveillance; and deciphering the molecular mechanisms of immunogenic cell death.
The ESMO Award for Immuno-Oncology was created this year in commemoration of the European pioneer in cancer research in immunology, founding member and first President of ESMO, Prof. Georges Mathé. It will be presented to Dr. Zitvogel during the ESMO Immuno-Oncology Congress 2017 taking place in Geneva, December 7–10, 2017. ■